Originally published byEU-Startups
Sightera Biosciences, an Antwerp-based AI drug discovery startup and spin-off from the University of Antwerp (UA) and Antwerp University Hospital (UZA), today announced the closing of a €3 million pre-Seed financing led by Entourage, Anacura and QBIC. The company plans to use this funding to expand the team, accelerate the expansion of its AI-native drug […]
The post Antwerp’s Sightera Biosciences raises €3 million to scale its patient-derived AI drug discovery platform appeared first on EU-Startups.
🌐
More news from European UnionEuropean Union
EUROPE
Related News
'If you're not AI-native, you're not getting funded': European fintech's H1 funding figures
14h ago
Inside Mistral’s monster fundraise and Palantir-like repositioning
11h ago
AI music platform Suno hits bum note as 55M users exposed in data breach, claims infosec expert
11h ago
New Unicorn! Humanoid secures €133 million at €1.1 billion valuation to scale industrial robotics and physical AI
10h ago
Why Europe doesn’t need another Silicon Valley to succeed
10h ago